Аналитики считают Structure Therapeutics более перспективной компанией, чем HUTCHMED

HUTCHMED (NASDAQ:HCM – Get Free Report) and Structure Therapeutics (NASDAQ:GPCR – Get Free Report) are both mid-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their profitability, risk, institutional ownership, earnings, valuation, dividends and analyst recommendations. Valuation & Earnings This table compares HUTCHMED and Structure Therapeutics”s gross revenue, earnings per share (EPS) and valuation. Profitability This table compares HUTCHMED and Structure Therapeutics’ net margins, return on equity and return on assets. Institutional and Insider Ownership 8.8% of HUTCHMED shares are owned by institutional investors. Comparatively, 91.8% of Structure Therapeutics shares are owned by institutional investors. 3.6% of HUTCHMED shares are owned by company insiders. Comparatively, 5.5% of Structure Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Volatility and Risk HUTCHMED has a beta of 0.23, suggesting that its stock price is 77% less volatile than the S&P 500. Comparatively, Structure Therapeutics has a beta of -1.43, suggesting that its stock price is 243% less volatile than the S&P 500. Analyst Ratings This is a breakdown of recent ratings and target prices for HUTCHMED and Structure Therapeutics, as provided by MarketBeat.com. HUTCHMED currently has a consensus price target of $14.87, indicating a potential upside of 21.36%. Structure Therapeutics has a consensus price target of $110.91, indicating a potential upside of 105.73%. Given Structure Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Structure Therapeutics is more favorable than HUTCHMED. Summary Structure Therapeutics beats HUTCHMED on 6 of the 11 factors compared between the two stocks. About HUTCHMED HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong. About Structure Therapeutics Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California. Receive News & Ratings for HUTCHMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HUTCHMED and related companies with MarketBeat.com's FREE daily email newsletter.